ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
PURPOSE: The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAF V600E-mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170 ). ANCHOR CRC aimed to evaluate efficacy, safety, and quality of life with first-line encorafenib + binimetinib + cetuximab in BRAF V600E-mutated mCRC. METHODS: In this multicenter, open-label, single-arm study, patients with BRAF V600E-mutated mCRC received oral encorafenib 300 mg once daily and binimetinib 45 mg twice daily in 28-day cycles, plus intravenous cetuximab 400 mg/m 2 once on day 1 of cycle 1, then 250 mg/m 2 once weekly for the first seven cycles, and 500 mg/m 2 once on Days 1 and 15 from cycle 8 onward. The primary end point was locally assessed confirmed objective response rate (cORR), and secondary end points included centrally assessed cORR, progression-free survival, overall survival (OS), quality of life, and safety and tolerability. RESULTS: Among 95 patients, the locally assessed cORR was 47.4% (95% CI, 37.0 to 57.9) with all partial responses. Since the lower limit of the 95% CI exceeded 30%, the primary end point was met. With a median follow-up duration of 20.1 months, the median progression-free survival on the basis of local assessments was 5.8 months and the median OS was 18.3 months. Treatment was well tolerated, with no unexpected toxicities. Using Patient Global Impression of Changes, substantial improvement in symptoms was consistently reported in ≥ 30% of patients from cycle 3 to cycle 10. CONCLUSION: The ANCHOR CRC study showed that the scientifically driven combination of encorafenib + binimetinib + cetuximab was active in the first-line setting of BRAF V600E-mutated mCRC with a manageable safety profile. Further first-line evaluation is ongoing (ClinicalTrails.gov identifier: NCT04607421 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 1×
“In patients with BRAF-mutated mCRC, the median overall survival (OS) reported with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) or doublet chemotherapy with or without the epidermal growth factor receptor (EGFR) antibody cetuximab was 10-14 months, the median progression-free survival (PFS) was 6-8 mo…”
BackgroundEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 9×
“EGFR-mediated extracellular-regulated kinase reactivation can be targeted by concurrently inhibiting EGFR and/or downstream extracellular regulated kinase signaling potentially through combination therapy with BRAF, mitogen-activated protein kinase (MEK), and EGFR inhibitors.21-23 The combination of the BRAF inhibitor…”
BackgroundResultInfluentialSelf-citationVan Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 3×
“Although cross-study comparisons have limited validity, overall, these results compare well with those of standard firstline chemotherapy-based regimens in BRAF-mutated mCRC.(4,8,17,28) In a pooled analysis of the CRYSTAL (FOLFIRI with or without cetuximab) and OPUS (FOLFOX-4 with or without cetuximab) studies, patien…”
BackgroundResultCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 8×
“EGFR-mediated extracellular-regulated kinase reactivation can be targeted by concurrently inhibiting EGFR and/or downstream extracellular regulated kinase signaling potentially through combination therapy with BRAF, mitogen-activated protein kinase (MEK), and EGFR inhibitors.21-23 The combination of the BRAF inhibitor…”
BackgroundInfluentialModest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw261 · Cited by 351
Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
Cited by
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501912 · Cited by 166
Self-citationBRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02541 · Cited by 92
Self-citationGuerrero, P., Albarrán, V., San Román, M., González-Merino, C., García de Quevedo, C., Moreno, J., Calvo, J. C., González, G., Orejana, I., Chamorro, J., et al. (2023) · Cancers · doi:10.3390/cancers15215243 · Cited by 21
Dankner, M., Dubé, L.-R., Sorin, M., Stein, A. J. B., Nowakowski, A., Park, C. L., Magrill, J., Lazaratos, A.-M., Romero, J. M., Batist, G., et al. (2025) · Current Oncology · doi:10.3390/curroncol32110624 · Cited by 3
Metadata
- Authors
- Van Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Grothey, A., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz-Casado, A., Graham, J., Kato, T., Ruffinelli, J. C., André, T., Carrière Roussel, E., Klauck, I., Groc, M., Vedovato, J.-C., & Tabernero, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2023-05-10
- Volume
- 41
- Issue
- 14
- Pages
- 2628-2637
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4319877706
- Cited by
- 103
- References
- 13
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1200/jco.22.01693
- The paper
- Van Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Grothey, A., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz-Casado, A., Graham, J., Kato, T., Ruffinelli, J. C., André, T., Carrière Roussel, E., Klauck, I., Groc, M., Vedovato, J.-C., & Tabernero, J. (2023). ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01693
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.